CD8A and neoplasm: Tumor vaccine fused with soluble PD-1 with the MUC1 gene showed good immunogenicity and anti-tumor effect by enhancing the activation of lymphocytes, and accumulates CD8+ tumor-infiltrating lymphocytes, resulting in reduced in tumor growth [49, 50].